224 related articles for article (PubMed ID: 31196476)
1. Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
Grinstein O; Krug B; Hellmic M; Siedek F; Malter W; Burke C; Schmutzler R; Maintz D; Rhiem K
Surg Oncol; 2019 Jun; 29():126-133. PubMed ID: 31196476
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
4. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
5. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
Garstka M; Henriquez A; Kelly BN; Webster A; Khubchandani JA; Hughes K; Nguyen A; Oseni T; Specht M; Coopey SB; Gadd MA; Smith BL
Ann Surg Oncol; 2021 Oct; 28(10):5657-5662. PubMed ID: 34296361
[TBL] [Abstract][Full Text] [Related]
6. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers.
Baltzer HL; Alonzo-Proulx O; Mainprize JG; Yaffe MJ; Metcalfe KA; Narod SA; Warner E; Semple JL
Ann Surg Oncol; 2014 May; 21(5):1583-8. PubMed ID: 24526546
[TBL] [Abstract][Full Text] [Related]
7. Impact of surgical variables on residual glandular tissue in risk-reducing mastectomies: Results of a retrospective monocentric study from a center of the German consortium for hereditary breast and ovarian cancer.
Mohrmann S; Kolberg L; Jäger B; Hoffmann J; Nestle-Krämling C; Zwiefel K; Friebe V; Sawicki LM; Bruckmann NM; Jannusch K; Morawitz J; Antoch G; Fehm TN; Kirchner J; Dietzel F
Eur J Surg Oncol; 2023 Nov; 49(11):107031. PubMed ID: 37683424
[TBL] [Abstract][Full Text] [Related]
8. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
[TBL] [Abstract][Full Text] [Related]
11. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
Stanek K; Zimovjanova M; Suk P; Jonas F; Zimovjanova A; Molitor M; Mestak O
Aesthetic Plast Surg; 2022 Apr; 46(2):706-711. PubMed ID: 34342702
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
[TBL] [Abstract][Full Text] [Related]
14. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P; de la Rochefordière A; Savignoni A; Falcou MC; Tardivon A; Thibault F; Alran S; Fourchotte V; Fitoussi A; Couturaud B; Dolbeault S; Salmon RJ; Sigal-Zafrani B; Asselain B; Stoppa-Lyonnet D;
Fam Cancer; 2012 Sep; 11(3):473-82. PubMed ID: 22711610
[TBL] [Abstract][Full Text] [Related]
15. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J; Metcalfe KA; Lynch HT; Kim-Sing C; Senter L; Pal T; Ainsworth P; Lubinski J; Tung N; Eng C; Gilchrist D; Blum J; Neuhausen SL; Singer CF; Ghadirian P; Sun P; Narod SA;
Ann Surg Oncol; 2013 Nov; 20(12):3817-22. PubMed ID: 23740344
[TBL] [Abstract][Full Text] [Related]
16. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
Wong SM; Ferroum A; Apostolova C; Alhassan B; Prakash I; Basik M; Boileau JF; Meterissian S; Aleynikova O; Wong N; Foulkes WD
Ann Surg Oncol; 2022 Oct; 29(11):6660-6668. PubMed ID: 35616744
[TBL] [Abstract][Full Text] [Related]
19. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
